Immuron Limited (IMC.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.038 (+2.70%) as of
Key statistics
- Market cap
- 12.27M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0260 – 0.0980
- Beta
- 0.47
- Revenue (TTM)
- 7.71M
- Profit margin
- -47.71%
- Volume
- 37.00k
About Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Carlton, VIC, Australia
- Employees
- 7
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.